Sirt result, page-49

Yes, its actually not bad given that infact I think the trial patients were really very advanced cases who had failed their "standard" treatments before being selected for what was really a "salvage" trial. Viewed in that context, we already know that nothing on offer will extend the OS beyond best supportive care if they have distant mets or complete occlusion of the PV.

What comes out of it is that SOR will probably make those patients more miserable and cost more than SIRT, and Per Protocol equivalent OS is exactly what you would expect. I am hopeful the FDA would give its approval to use it to treat HCC based on those results.

I was just hoping they had enough less advanced cases in the mix where SIRT could show its advantage in OS.

C'est la vie.